PMID- 28282717
OWN - NLM
STAT- MEDLINE
DCOM- 20170602
LR  - 20181202
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 55
IP  - 3
DP  - 2017 Mar
TI  - Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope.
PG  - 166-174
AB  - Type 2 diabetes mellitus (T2DM) is recognized as a public health problem and 
      increasingly prevalent illness. Key elements of the guideline for diabetes care 
      are based on evidence-based medicine approach and apply for population, not 
      individuals. However, individualized care can improve diabetes management. 
      Personalized medicine is otherwise called precision medicine tries to find better 
      prediction, prevention, and intervention for T2DM individuals. Precision medicine 
      in diabetes refers to the utility of genomics data of a patient with diabetes to 
      provide the most effective diagnosis strategies and treatment plans. Over 100 
      genetic loci influence susceptibility to T2DM. Genomics data together with the 
      potential of other "Omics" and clinical evidence-based data will lead to diabetes 
      care improvement in the context of personalized medicine in the near future. 
      Breakthrough of technologies enables much greater improvements in the 
      understanding of individual variations that may alter the T2DM outcome. This 
      article represents a comprehensive review of current knowledge on the impact of 
      personalized medicine in T2DM.
FAU - Aghaei Meybodi, Hamid Reza
AU  - Aghaei Meybodi HR
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Hasanzad, Mandana
AU  - Hasanzad M
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 
      AND Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad 
      Univeristy, Tehran, Iran.
FAU - Larijani, Bagher
AU  - Larijani B
AD  - Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
SB  - IM
MH  - Diabetes Mellitus, Type 2/*genetics/*therapy
MH  - *Genomics
MH  - Humans
MH  - *Precision Medicine
OTO - NOTNLM
OT  - Diabetes care
OT  - Omics
OT  - Personalized medicine
OT  - Type 2 diabetes mellitus
EDAT- 2017/03/12 06:00
MHDA- 2017/06/03 06:00
CRDT- 2017/03/12 06:00
PHST- 2017/03/06 00:00 [accepted]
PHST- 2017/03/12 06:00 [entrez]
PHST- 2017/03/12 06:00 [pubmed]
PHST- 2017/06/03 06:00 [medline]
PST - ppublish
SO  - Acta Med Iran. 2017 Mar;55(3):166-174.